JP2020007330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020007330A5 JP2020007330A5 JP2019151759A JP2019151759A JP2020007330A5 JP 2020007330 A5 JP2020007330 A5 JP 2020007330A5 JP 2019151759 A JP2019151759 A JP 2019151759A JP 2019151759 A JP2019151759 A JP 2019151759A JP 2020007330 A5 JP2020007330 A5 JP 2020007330A5
- Authority
- JP
- Japan
- Prior art keywords
- protein transduction
- transduction reagent
- reagent modified
- modified
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 74
- 108090000623 proteins and genes Proteins 0.000 claims 74
- 239000003153 chemical reaction reagent Substances 0.000 claims 72
- 238000010361 transduction Methods 0.000 claims 71
- 230000026683 transduction Effects 0.000 claims 71
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 claims 6
- 101150027852 pou3f2 gene Proteins 0.000 claims 6
- 102100024630 Asc-type amino acid transporter 1 Human genes 0.000 claims 4
- 101150081875 Slc7a10 gene Proteins 0.000 claims 4
- 101150010353 Ascl1 gene Proteins 0.000 claims 3
- 230000000451 tissue damage Effects 0.000 claims 3
- 231100000827 tissue damage Toxicity 0.000 claims 3
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 2
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 2
- 101150051240 DLX2 gene Proteins 0.000 claims 2
- 108700042694 Lhx3 Proteins 0.000 claims 2
- 101150026563 NR4A2 gene Proteins 0.000 claims 2
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 claims 2
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 claims 2
- 102100038554 Neurogenin-2 Human genes 0.000 claims 2
- 208000016222 Pancreatic disease Diseases 0.000 claims 2
- 229920002873 Polyethylenimine Polymers 0.000 claims 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims 2
- 101150106167 SOX9 gene Proteins 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- 238000007910 systemic administration Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000012096 transfection reagent Substances 0.000 claims 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- HKYPYRMYYCHDFR-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC.NCC(O)=O Chemical compound CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC.NCC(O)=O HKYPYRMYYCHDFR-UHFFFAOYSA-N 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 claims 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 claims 1
- 101150089574 FOXA3 gene Proteins 0.000 claims 1
- 101150026630 FOXG1 gene Proteins 0.000 claims 1
- 101150057663 Foxa2 gene Proteins 0.000 claims 1
- 101150005295 GATA2 gene Proteins 0.000 claims 1
- 101150003775 HNF1A gene Proteins 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010060820 Joint injury Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 101100012009 Mus musculus Etv2 gene Proteins 0.000 claims 1
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 claims 1
- 101100310650 Mus musculus Sox18 gene Proteins 0.000 claims 1
- 101100043062 Mus musculus Sox7 gene Proteins 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000029549 Muscle injury Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 101150075928 Pax4 gene Proteins 0.000 claims 1
- 102100040923 Protein flightless-1 homolog Human genes 0.000 claims 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 claims 1
- 101100008069 Rattus norvegicus Cuzd1 gene Proteins 0.000 claims 1
- 101100517253 Rattus norvegicus Nsf gene Proteins 0.000 claims 1
- 101150076597 SQLE gene Proteins 0.000 claims 1
- 101150058731 STAT5A gene Proteins 0.000 claims 1
- 101150117830 Sox5 gene Proteins 0.000 claims 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims 1
- 102100027654 Transcription factor PU.1 Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 101001025061 Xenopus laevis Forkhead box protein C1-A Proteins 0.000 claims 1
- 101000818331 Xenopus tropicalis Forkhead box protein C2 Proteins 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 229920001222 biopolymer Polymers 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000030270 breast disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 101150003286 gata4 gene Proteins 0.000 claims 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 108010008929 proto-oncogene protein Spi-1 Proteins 0.000 claims 1
- 101150055666 sox6 gene Proteins 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895562P | 2013-10-25 | 2013-10-25 | |
| US61/895,562 | 2013-10-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018187189A Division JP6577112B2 (ja) | 2013-10-25 | 2018-10-02 | タンパク質誘導生体内細胞リプログラミングによる細胞転換に関する方法、システム、及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020007330A JP2020007330A (ja) | 2020-01-16 |
| JP2020007330A5 true JP2020007330A5 (enExample) | 2020-06-25 |
| JP6880125B2 JP6880125B2 (ja) | 2021-06-02 |
Family
ID=52993686
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550686A Active JP6415582B2 (ja) | 2013-10-25 | 2014-10-27 | タンパク質誘導生体内細胞リプログラミングによる細胞転換に関する方法、システム、及び組成物 |
| JP2018187189A Active JP6577112B2 (ja) | 2013-10-25 | 2018-10-02 | タンパク質誘導生体内細胞リプログラミングによる細胞転換に関する方法、システム、及び組成物 |
| JP2019151759A Active JP6880125B2 (ja) | 2013-10-25 | 2019-08-22 | タンパク質誘導生体内細胞リプログラミングによる細胞転換に関する方法、システム、及び組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550686A Active JP6415582B2 (ja) | 2013-10-25 | 2014-10-27 | タンパク質誘導生体内細胞リプログラミングによる細胞転換に関する方法、システム、及び組成物 |
| JP2018187189A Active JP6577112B2 (ja) | 2013-10-25 | 2018-10-02 | タンパク質誘導生体内細胞リプログラミングによる細胞転換に関する方法、システム、及び組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10076574B2 (enExample) |
| EP (2) | EP3954381A1 (enExample) |
| JP (3) | JP6415582B2 (enExample) |
| KR (2) | KR102113829B1 (enExample) |
| CN (2) | CN106170295B (enExample) |
| AU (3) | AU2014339843B2 (enExample) |
| CA (2) | CA3194454A1 (enExample) |
| DK (1) | DK3060237T3 (enExample) |
| ES (1) | ES2896021T3 (enExample) |
| IL (3) | IL245300B (enExample) |
| PL (1) | PL3060237T3 (enExample) |
| PT (1) | PT3060237T (enExample) |
| SG (1) | SG11201603230UA (enExample) |
| WO (1) | WO2015061779A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| JP6530206B2 (ja) * | 2015-03-17 | 2019-06-12 | 学校法人同志社 | 上皮間葉転換阻害剤及び癌転移治療剤 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CN106110297B (zh) * | 2016-07-05 | 2019-12-17 | 南通大学 | Gfi1截短体的应用 |
| CN110536685A (zh) * | 2016-12-23 | 2019-12-03 | 昆士兰大学 | Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病 |
| JP2018132365A (ja) * | 2017-02-14 | 2018-08-23 | 株式会社神戸製鋼所 | マーキング装置 |
| AU2018375192B2 (en) | 2017-12-01 | 2023-11-09 | Encoded Therapeutics, Inc. | Engineered DNA binding proteins |
| US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
| US11001618B2 (en) | 2018-03-02 | 2021-05-11 | Northwestern University | Overexpression of FOXC1 to treat corneal vascularization |
| US11340226B2 (en) * | 2018-03-02 | 2022-05-24 | The Chinese University Of Hong Kong | Squalene epoxidase in the diagnosis and treatment of non-alcoholic fatty liver diseases |
| JP7217542B2 (ja) * | 2018-03-29 | 2023-02-03 | 国立大学法人 琉球大学 | 分化コントロール化合物を用いて造腫瘍性をもつおそれのある未分化ｉＰＳ細胞等の混入を除去する方法 |
| US12274733B2 (en) | 2018-09-28 | 2025-04-15 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| AU2019347666B2 (en) | 2018-09-28 | 2025-10-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| EP3942018A4 (en) * | 2019-03-17 | 2022-12-07 | Baylor College of Medicine | Direct reprogramming of cardiac fibroblasts into cardiomyocytes using an endothelial cell transdifferentiation strategy |
| CN113710285A (zh) * | 2019-03-26 | 2021-11-26 | 宾州研究基金会 | 用于治疗癌症的方法和材料 |
| KR102150489B1 (ko) * | 2019-04-09 | 2020-09-01 | 고려대학교 산학협력단 | 소변세포로부터 신장전구세포로의 직접 역분화를 유도하는 방법 및 이의 방법으로 역분화된 신장전구세포를 포함하는 신장세포 손상 질환 예방 또는 치료용 약학 조성물 |
| US20210162002A1 (en) * | 2019-10-17 | 2021-06-03 | The Penn State Research Foundation | Regenerating functional neurons for treatment of spinal cord injury and als |
| JP2022552002A (ja) * | 2019-10-17 | 2022-12-14 | ザ・ペン・ステイト・リサーチ・ファウンデイション | 出血性脳卒中の治療のための機能的ニューロンの再生 |
| CN114630699A (zh) * | 2019-10-17 | 2022-06-14 | 宾州研究基金会 | 再生功能神经元以用于治疗神经病症 |
| WO2021108609A1 (en) * | 2019-11-25 | 2021-06-03 | The Penn State Research Foundation | Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion |
| CN112877364B (zh) * | 2019-11-29 | 2023-07-28 | 中国医学科学院药物研究所 | 软骨下骨细胞向关节软骨细胞直接转化的重编程诱导方案 |
| JPWO2021149823A1 (enExample) * | 2020-01-24 | 2021-07-29 | ||
| CN111214660B (zh) * | 2020-02-25 | 2022-01-18 | 北京大学第三医院（北京大学第三临床医学院） | Pax4基因表达抑制剂在制备抑制纤维化的药物中的应用 |
| US11091524B1 (en) | 2020-04-22 | 2021-08-17 | Houston Gene Therapeutics Llc | Compositions for treatment of vascular disease |
| CN114231489A (zh) * | 2020-09-08 | 2022-03-25 | 纽伦捷生物医药科技（苏州）有限公司 | 用于重编程的功能性片段、组合及其应用 |
| JP2023543360A (ja) * | 2020-09-29 | 2023-10-13 | ニューエクセル・セラピューティクス・インコーポレイテッド | Ｄｌｘ２ベクター |
| CA3197178A1 (en) * | 2020-09-29 | 2022-04-07 | NeuExcell Therapeutics Inc. | Neurod1 combination vector |
| EP4221836A4 (en) * | 2020-09-29 | 2025-02-19 | Neuexcell Therapeutics Inc. | NEUROD1 AND DLX2 VECTOR |
| JP2022104813A (ja) * | 2020-12-29 | 2022-07-11 | アイ ピース，インコーポレイテッド | リプログラミング因子を導入された細胞の培養方法 |
| CN113563428B (zh) * | 2021-06-22 | 2022-08-02 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 特定空间结构多肽及其在制备iPSC中的应用 |
| CN117070477A (zh) * | 2022-05-10 | 2023-11-17 | 纽伦捷生物医药科技（上海）有限公司 | 重组溶瘤病毒的重编程的功能性片段、组合及其应用 |
| WO2024112118A1 (ko) * | 2022-11-25 | 2024-05-30 | 고려대학교 산학협력단 | 방사선 치료에 의하여 손상된 근육 재생을 위한 고기능성 세포 치료제 조성물 |
| US12252518B2 (en) | 2023-01-06 | 2025-03-18 | Life Biosciences, Inc. | Methods of treating non-arteritic anterior ischemic optic neuropathy |
| WO2025106947A1 (en) * | 2023-11-17 | 2025-05-22 | Exir, Inc. | Compositions and methods for induced stem cell differentiation to neuronal lineage |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| EP0671926B1 (en) | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| FR2766195A1 (fr) | 1997-07-21 | 1999-01-22 | Transgene Sa | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique |
| DE19839491A1 (de) | 1998-08-29 | 2000-03-02 | Hermann Heumann | Verfahren zur Markierung von Biopolymeren mit Isotopen |
| US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
| DE60230147D1 (de) | 2001-07-06 | 2009-01-15 | Merck Patent Gmbh | Verfahren zur überwachung und modulierung von proteinfaltung |
| WO2003046160A2 (en) | 2001-11-30 | 2003-06-05 | Applied Research Systems Ars Holding N.V. | Methods of increasing protein expression levels |
| US20030134352A1 (en) | 2002-01-04 | 2003-07-17 | Freimuth Paul I. | Facilitating protein folding and solubility by use of peptide extensions |
| CA2471178A1 (en) | 2002-01-07 | 2003-07-17 | European Molecular Biology Laboratory | Recombinant protein expression |
| WO2005026196A2 (en) | 2003-09-12 | 2005-03-24 | Novexin Limited | Methods for folding proteins and reducing protein aggregation |
| CA2548202C (en) | 2003-11-25 | 2013-05-14 | The Government Of The United States, As Represented By The Secretary Of The Army | Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| CN101528267A (zh) | 2006-10-25 | 2009-09-09 | 皇家飞利浦电子股份有限公司 | 用于检测前列腺癌的造影剂 |
| SG10202103401QA (en) | 2008-03-17 | 2021-05-28 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| US8722348B2 (en) | 2008-05-28 | 2014-05-13 | Wayne State University | Method and composition for a protein transduction technology and its applications |
| CN102272142A (zh) * | 2008-12-23 | 2011-12-07 | 帷幄生物技术公司 | 非遗传修饰性重编程细胞的组合物和方法 |
| EP2414510A4 (en) | 2009-04-03 | 2013-04-17 | Mclean Hospital Corp | INDUCED PLURIPOTENTIAL STEM CELLS |
| US20120115225A1 (en) | 2009-04-23 | 2012-05-10 | Xu C W | Reprogramming of somatic cells with purified proteins |
| EP2253700A1 (en) | 2009-05-13 | 2010-11-24 | Helmholtz-Zentrum für Infektionsforschung GmbH | A method for producing test systems from donors suffering from adverse effects of medicaments and /or medical treatments, and uses of said systems |
| JP2013510563A (ja) | 2009-11-13 | 2013-03-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 操作された微小胞を用いた真核細胞のリプログラミング |
| JP2011135864A (ja) * | 2009-12-30 | 2011-07-14 | Korea Univ Research & Business Foundation | Ｏｃｔ４及びＢｍｉ１、またはその上位調節子を用いて体細胞から胚幹細胞類似細胞への逆分化を誘導する組成物及びこれを用いた胚幹細胞類似細胞の製造方法 |
| JP2013518587A (ja) * | 2010-02-04 | 2013-05-23 | ヴィヴォスクリプト，インコーポレイテッド | 神経学的障害を治療するために遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法 |
| KR101788903B1 (ko) * | 2010-08-19 | 2017-10-23 | 에프. 호프만-라 로슈 아게 | 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (ｉｒｎｓｃｓ) 로의 전환 |
| WO2012116064A1 (en) * | 2011-02-22 | 2012-08-30 | The Board Of Regents Of The University Of Texas | Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes |
| WO2012151234A2 (en) | 2011-05-02 | 2012-11-08 | Wayne State University | A protein-induced pluripotent cell technology uses thereof |
| US20140289882A1 (en) * | 2011-07-19 | 2014-09-25 | Oregon Health And Science University | Compositions and methods for re-programming cells without genetic modification for repairing cartilage damage |
| JP6298405B2 (ja) | 2011-08-30 | 2018-03-20 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 心筋細胞を生成するための方法 |
| US20180223260A1 (en) * | 2011-10-21 | 2018-08-09 | Stemgenics, Inc. | Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use |
-
2014
- 2014-10-27 PT PT148550403T patent/PT3060237T/pt unknown
- 2014-10-27 EP EP21187708.9A patent/EP3954381A1/en not_active Withdrawn
- 2014-10-27 CN CN201480071293.0A patent/CN106170295B/zh active Active
- 2014-10-27 ES ES14855040T patent/ES2896021T3/es active Active
- 2014-10-27 CA CA3194454A patent/CA3194454A1/en active Pending
- 2014-10-27 US US15/031,839 patent/US10076574B2/en active Active
- 2014-10-27 JP JP2016550686A patent/JP6415582B2/ja active Active
- 2014-10-27 KR KR1020167013867A patent/KR102113829B1/ko active Active
- 2014-10-27 WO PCT/US2014/062400 patent/WO2015061779A1/en not_active Ceased
- 2014-10-27 EP EP14855040.3A patent/EP3060237B1/en active Active
- 2014-10-27 DK DK14855040.3T patent/DK3060237T3/da active
- 2014-10-27 PL PL14855040T patent/PL3060237T3/pl unknown
- 2014-10-27 KR KR1020207014071A patent/KR20200057108A/ko not_active Ceased
- 2014-10-27 CA CA2934065A patent/CA2934065C/en active Active
- 2014-10-27 SG SG11201603230UA patent/SG11201603230UA/en unknown
- 2014-10-27 CN CN202011127974.8A patent/CN112245592A/zh active Pending
- 2014-10-27 AU AU2014339843A patent/AU2014339843B2/en active Active
-
2016
- 2016-04-25 IL IL245300A patent/IL245300B/en active IP Right Grant
-
2018
- 2018-09-04 US US16/120,829 patent/US10548983B2/en active Active
- 2018-10-02 JP JP2018187189A patent/JP6577112B2/ja active Active
-
2019
- 2019-05-19 IL IL266705A patent/IL266705B/en active IP Right Grant
- 2019-06-28 AU AU2019204630A patent/AU2019204630C1/en active Active
- 2019-08-22 JP JP2019151759A patent/JP6880125B2/ja active Active
-
2020
- 2020-01-28 IL IL272324A patent/IL272324B/en unknown
-
2021
- 2021-06-29 AU AU2021204485A patent/AU2021204485B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020007330A5 (enExample) | ||
| JP2017503849A5 (enExample) | ||
| Torreggiani et al. | Multimodal transfer of MDR by exosomes in human osteosarcoma | |
| Xu et al. | Exosomal miRNA-128-3p from mesenchymal stem cells of aged rats regulates osteogenesis and bone fracture healing by targeting Smad5 | |
| Rizzi et al. | NGF steers microglia toward a neuroprotective phenotype | |
| Luz-Madrigal et al. | Reprogramming of the chick retinal pigmented epithelium after retinal injury | |
| Wang et al. | MicroRNA‐145 as one negative regulator of astrogliosis | |
| MX2018002099A (es) | Compuestos y métodos para la administración transmembranal de moléculas. | |
| Orange et al. | Coley’s lessons remembered: augmenting mistletoe therapy | |
| Matsuura et al. | Mesenchymal stem cells ameliorate cerebellar pathology in a mouse model of spinocerebellar ataxia type 1 | |
| EP3423056A1 (en) | Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors | |
| BR112015011729A2 (pt) | dispositivo de perfusão adesivo de vários dias para administração transdérmica de rotigotina | |
| Gerhart et al. | Antibody-conjugated, DNA-based nanocarriers intercalated with doxorubicin eliminate myofibroblasts in explants of human lens tissue | |
| FI3443010T3 (fi) | Uusia anti-sirp -vasta-aineita ja niiden terapeuttisia sovelluksia | |
| BR112022002116A2 (pt) | Filme, método de tratamento de uma doença ou condição, uso de um filme e método de fabricação de um filme | |
| Hara et al. | Fluocinolone acetonide is a potent synergistic factor of TGF‐β3–associated chondrogenesis of bone marrow–derived mesenchymal stem cells for articular surface regeneration | |
| US20250248946A1 (en) | Methods and compositions for immune cell rejuvenation and therapies using rejuvenated immune cells | |
| Qian et al. | Protective role of adipose-derived stem cells in Staphylococcus aureus-induced lung injury is mediated by RegIIIγ secretion | |
| Torres-Velarde et al. | Mechanisms of stress-related muscle atrophy in fish: An ex vivo approach | |
| Ono et al. | Silencing p27 reverses post-mitotic state of supporting cells in neonatal mouse cochleae | |
| van Tongeren et al. | Synergy between TLR-2 and TLR-3 signaling in primary human nasal epithelial cells | |
| Guo et al. | Growth and Turning Properties of Adult Glial Cell–Derived Neurotrophic Factor Coreceptor α1 Nonpeptidergic Sensory Neurons | |
| Sandonà et al. | Amniotic membrane-derived stromal cells release extracellular vesicles that favor regeneration of dystrophic skeletal muscles | |
| Kim et al. | Oligodendrocyte precursor cells stop sensory axons regenerating into the spinal cord | |
| Akar et al. | Generation of highly pure pluripotent stem cell-derived myogenic progenitor cells and myotubes |